Eric Eldering

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7449767/publications.pdf

Version: 2024-02-01

135 papers	5,331 citations	76326 40 h-index	88630 70 g-index
137 all docs	137 docs citations	137 times ranked	7849 citing authors

#	Article	IF	Citations
1	A BAFFling <i>mÃ©nage Ã trois</i> in mantle cell lymphoma. Haematologica, 2022, 107, 2774-2775.	3.5	2
2	Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment. Blood, 2022, 140, 630-643.	1.4	14
3	Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas. Cancer Research Communications, 2022, 2, 330-341.	1.7	6
4	Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma. Leukemia, 2022, 36, 2165-2176.	7.2	8
5	Human CXCR5⁺PDâ€1⁺ CD8 T cells in healthy individuals and patients with hematologic malignancies. European Journal of Immunology, 2021, 51, 703-713.	2.9	11
6	Regulation of Bcl-XL by non-canonical NF-ÎºB in the context of CD40-induced drug resistance in CLL. Cell Death and Differentiation, 2021, 28, 1658-1668.	11.2	41
7	Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19. Blood Advances, 2021, 5, 913-925.	5.2	11
8	Phosphatase PP2A enhances MCL-1 protein half-life in multiple myeloma cells. Cell Death and Disease, 2021, 12, 229.	6.3	15
9	T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective. Haematologica, 2021, 106, 1234-1243.	3.5	18
10	Combined ibrutinib and venetoclax treatment vs single agents in the <i>TCL1</i> mouse model of chronic lymphocytic leukemia. Blood Advances, 2021, 5, 5410-5414.	5.2	20
11	Hematopoietic versus Solid Cancers and T Cell Dysfunction: Looking for Similarities and Distinctions. Cancers, 2021, 13, 284.	3.7	15
12	Targeting Metabolic Alterations in CLL Microenvironment; Inhibition of Glutamine Import Attenuates Venetoclax Resistance. Blood, 2021, 138, 3717-3717.	1.4	0
13	Ibrutinib Treatment in CLL Interrupts CD40 Signaling Capacity and Sensitizes CLL Cells to Venetoclax. Blood, 2021, 138, 1545-1545.	1.4	3
14	Chronic Lymphocytic Leukemia Actively Induces T-Cell Dysfunction By Contact-Dependent Signaling Via CD24 and CD52. Blood, 2021, 138, 3714-3714.	1.4	1
15	Overexpression of SH2-Containing Inositol Phosphatase Contributes to Chronic Lymphocytic Leukemia Survival. Journal of Immunology, 2020, 204, 360-374.	0.8	6
16	Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. Journal of Clinical Oncology, 2020, 38, 4042-4054.	1.6	141
17	AKT signaling restrains tumor suppressive functions of FOXO transcription factors and GSK3 kinase in multiple myeloma. Blood Advances, 2020, 4, 4151-4164.	5.2	20
18	Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing?. Frontiers in Oncology, 2020, 10, 592205.	2.8	31

#	Article	IF	Citations
19	Eomes broadens the scope of CD8 T-cell memory by inhibiting apoptosis in cells of low affinity. PLoS Biology, 2020, 18, e3000648.	5.6	31
20	CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells. , 2020, 8, e000218.		19
21	Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. Blood, 2020, 136, 2918-2926.	1.4	67
22	Starvation and antimetabolic therapy promote cytokine release and recruitment of immune cells. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 9932-9941.	7.1	64
23	The Effect of SF3B1 Mutation on the DNA Damage Response and Nonsense-Mediated mRNA Decay in Cancer. Frontiers in Oncology, 2020, 10, 609409.	2.8	15
24	Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study. Haematologica, 2020, 106, 87-97.	3.5	43
25	Development of a Novel Lymph Node-Based 3D Culture System Promoting Chronic Lymphocytic Leukemia Proliferation and Survival. Blood, 2020, 136, 47-48.	1.4	0
26	Electron Transport Chain Inhibition Suppresses CD40 Expression and Sensitizes Chronic Lymphocytic Leukaemia Cells to Venetoclax. Blood, 2020, 136, 35-35.	1.4	0
27	Effects of Ibrutinib on Metabolic Alterations and Micro-Environmental Signalling in Chronic Lymphocytic Leukaemia. Blood, 2020, 136, 36-37.	1.4	1
28	Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia. Leukemia, 2019, 33, 390-402.	7.2	44
29	The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors. Cell Cycle, 2019, 18, 2307-2322.	2.6	5
30	Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences, 2019, 20, 4315.	4.1	21
31	Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes. Journal of Immunology, 2019, 203, 2100-2109.	0.8	16
32	Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy. Blood, 2019, 134, 44-58.	1.4	118
33	Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment. Blood Advances, 2019, 3, 2642-2652.	5.2	79
34	Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented In Vitro by Adequate Activating Signaling. HemaSphere, 2019, 3, e308.	2.7	14
35	Cross-Talk between Cytokine and NF-Ä¸b Signaling in the CLL Microenvironment Can Affect Sensitivity for Venetoclax. Blood, 2019, 134, 5449-5449.	1.4	0
36	CD3xCD19 Dart Treatment Is Efficient in Venetoclax Resistant CLL and Reverses T Cell Dysfunction. Blood, 2019, 134, 3043-3043.	1.4	0

#	Article	IF	Citations
37	Linking Microenvironmental Signals to Metabolic Switches and Drug Responses in Chronic Lymphocytic Leukemia. Blood, 2019, 134, 479-479.	1.4	1
38	Improving CLL VÎ³9VÎ´2-Tâ€“cell fitness for cellular therapy by ex vivo activation and ibrutinib. Blood, 2018, 132, 2260-2272.	1.4	39
39	Chronic Lymphocytic Leukemia Cells Impair Mitochondrial Fitness in CD8+ T Cells and Impede CAR T Cell Efficacy. Blood, 2018, 132, 235-235.	1.4	2
40	First Evidence of Restoration of T and NK Cell Compartment after Venetoclax Treatment. Blood, 2018, 132, 1860-1860.	1.4	5
41	The GAIA (CLL13) trial: An international intergroup phase III study for frontline therapy in chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology, 2018, 36, TPS7582-TPS7582.	1.6	7
42	A New Therapeutic Hypothesis: Nonsense-Mediated Decay Is an Exploitable Target in Multiple Myeloma. Blood, 2018, 132, 1937-1937.	1.4	0
43	First Evidence of Dysfunctional Antigen-Specific T Cell Responses in Experimental CLL As a Model for Studies of Autologous T Cell-Based Therapies. Blood, 2018, 132, 3694-3694.	1.4	0
44	CD40 signaling instructs chronic lymphocytic leukemia cells to attract monocytes via the CCR2 axis. Haematologica, 2017, 102, 2069-2076.	3.5	11
45	Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk. Haematologica, 2017, 102, 1469-1476.	3.5	52
46	Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancer. Expert Opinion on Therapeutic Targets, 2017, 21, 767-779.	3.4	62
47	Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling. Cell Death and Differentiation, 2017, 24, 111-119.	11.2	29
48	Chronic lymphocytic leukemia development is accelerated in mice with deficiency of the pro-apoptotic regulator NOXA. Haematologica, 2016, 101, e374-e377.	3.5	6
49	Antigen-affinity controls pre-germinal center B cell selection by promoting Mcl-1 induction through BAFF receptor signaling. Scientific Reports, 2016, 6, 35673.	3.3	11
50	Bcl-2 Members As Drug Target and Biomarkers for Response to Ibrutinib and Venetoclax in CLL. Blood, 2016, 128, 2043-2043.	1.4	3
51	Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Haematologica, 2015, 100, e302-6.	3.5	100
52	Blimpâ€1 homolog Hobit identifies effectorâ€type lymphocytes in humans. European Journal of Immunology, 2015, 45, 2945-2958.	2.9	94
53	Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia. Leukemia and Lymphoma, 2015, 56, 2439-2447.	1.3	6
54	Targeting BCR-Independent Proliferation of CLL Cells. Blood, 2015, 126, 2916-2916.	1.4	0

#	Article	IF	Citations
55	CLL Disease Severity Is Enhanced in Tcl1 Mice Deficient for Pro-Apoptotic Regulator Noxa. Blood, 2015, 126, 4144-4144.	1.4	0
56	Assessment of <scp>TP</scp>53 functionality in chronic lymphocytic leukaemia by different assays; an <scp>ERIC</scp>â€wide approach. British Journal of Haematology, 2014, 167, 565-569.	2.5	7
57	Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: A multicenter phase 2 study. Leukemia Research, 2014, 38, 34-41.	0.8	24
58	CMV-specific CD8+ T-cell function is not impaired in chronic lymphocytic leukemia. Blood, 2014, 123, 717-724.	1.4	53
59	miR in CLL: more than mere markers of prognosis?. Blood, 2014, 124, 2-4.	1.4	0
60	Combined Inhibition of mTOR and DNA-PK Blocks Survival, Adhesion, Proliferation and Chemoresistance in Primary Chronic Lymphocytic Leukemia (CLL) Cells. Blood, 2014, 124, 1981-1981.	1.4	3
61	Combined Inhibition of Phosphatidylinositol 3-Kinase (PI3K) Isoform Î± and Î´ By the Pan-Class I PI3K Inhibitor SAR245409 (XL765) in Primary Chronic Lymphocytic Leukemia Cells Blocks Survival, Adhesion and Proliferation. Blood, 2014, 124, 4691-4691.	1.4	1
62	IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. Blood, 2013, 122, 3010-3019.	1.4	107
63	BH3-only protein Noxa contributes to apoptotic control of stress-erythropoiesis. Apoptosis: an International Journal on Programmed Cell Death, 2013, 18, 1306-1318.	4.9	10
64	The biological rationale and clinical efficacy of inhibition of signaling kinases in chronic lymphocytic leukemia. Leukemia Research, 2013, 37, 838-847.	0.8	5
65	Overview of available p53 function tests in relation toTP53andATMgene alterations and chemoresistance in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2013, 54, 1849-1853.	1.3	15
66	Effect of oxidative stress on respiratory epithelium from children with Down syndrome. European Respiratory Journal, 2013, 42, 1037-1045.	6.7	5
67	Pro-Apoptotic Protein Noxa Regulates Memory T Cell Population Size and Protects against Lethal Immunopathology. Journal of Immunology, 2013, 190, 1180-1191.	0.8	22
68	The Impact Of Subclonal Versus Clonal Novel Recurrent Mutations On Treatment Outcome In Previously Untreated High Risk CLL Patients: Results From The HOVON68 Trial. Blood, 2013, 122, 2861-2861.	1.4	1
69	Possible Mechanisms Of Resistance To The Novel BH3-Mimetic ABT-199 In In Vitro Lymph Node Models Of CLL â€“ The Role Of Abl and Btk. Blood, 2013, 122, 4188-4188.	1.4	6
70	CMV-Specific CD8+ T-CELL Function Is NOT Impaired In CLL. Blood, 2013, 122, 2862-2862.	1.4	0
71	Viral double-stranded RNA sensors induce antiviral, pro-inflammatory, and pro-apoptotic responses in human renal tubular epithelial cells. Kidney International, 2012, 82, 664-675.	5.2	18
72	CD70-Driven Costimulation Induces Survival or Fas-Mediated Apoptosis of T Cells Depending on Antigenic Load. Journal of Immunology, 2012, 188, 4256-4267.	0.8	21

#	Article	IF	Citations
73	Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2012, 18, 487-498.	7.0	88
74	Notch controls the magnitude of T helper cell responses by promoting cellular longevity. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9041-9046.	7.1	54
75	BH3-only protein Noxa regulates apoptosis in activated B cells and controls high-affinity antibody formation. Blood, 2012, 119, 1440-1449.	1.4	33
76	The fourth dimension in immunological space: how the struggle for nutrients selects highâ€affinity lymphocytes. Immunological Reviews, 2012, 249, 84-103.	6.0	18
77	The clinically active BTK inhibitor PCI-32765 targets B-cell receptorâ€“ and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood, 2012, 119, 2590-2594.	1.4	493
78	Assessment of p53 Functionality in Chronic Lymphocytic Leukemia by Different Assays; An Eric-Wide Approach.. Blood, 2012, 120, 2872-2872.	1.4	1
79	SF3B1 Mutations in CLL Are Equivalent to p53/ATM Dysfunction and Cause Defective Puma Upregulation in Response to Chemotherapy. Blood, 2012, 120, 711-711.	1.4	5
80	The Broad Kinase Inhibitor Dasatinib in Combination with Fludarabine in Patients with Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase 2 Study. Blood, 2012, 120, 1798-1798.	1.4	1
81	Mapping the Targets of Dasatinib in Chronic Lymphocytic Leukemia Reveals Distinct Roles for Abl and Btk in Drug Resistance and Adhesion, and Explains Clinical Effects On Lymph Node Reduction. Blood, 2012, 120, 3900-3900.	1.4	2
82	DNA damageâ€induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing. Blood, 2011, 117, 1622-1632.	1.4	35
83	WNT signaling controls expression of pro-apoptotic BOK and BAX in intestinal cancer. Biochemical and Biophysical Research Communications, 2011, 406, 1-6.	2.1	26
84	Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas. Blood, 2011, 117, 6856-6865.	1.4	47
85	CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101. Blood, 2011, 118, 5178-5188.	1.4	44
86	Apoptosis induced by overall metabolic stress converges on the Bcl-2 family proteins Noxa and Mcl-1. Apoptosis: an International Journal on Programmed Cell Death, 2011, 16, 708-721.	4.9	52
87	The Costimulatory Molecule CD27 Maintains Clonally Diverse CD8+ T Cell Responses of Low Antigen Affinity to Protect against Viral Variants. Immunity, 2011, 35, 97-108.	14.3	121
88	Role of T Cell-Derived IL-21 in the Proliferation of Chronic Lymphocytic Leukemia Cells,. Blood, 2011, 118, 3871-3871.	1.4	0
89	Histone Deacetylase Inhibitors Suppress Inflammatory Activation of Rheumatoid Arthritis Patient Synovial Macrophages and Tissue. Journal of Immunology, 2010, 184, 2718-2728.	0.8	208
90	Apoptosis Threshold Set by Noxa and Mcl-1 after T Cell Activation Regulates Competitive Selection of High-Affinity Clones. Immunity, 2010, 32, 754-765.	14.3	78

#	Article	IF	Citations
91	Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells. Haematologica, 2010, 95, 1510-1518.	3.5	73
92	CD20 deficiency in humans results in impaired T cellâ€“independent antibody responses. Journal of Clinical Investigation, 2010, 120, 214-222.	8.2	324
93	CD40 Stimulation Sensitizes CLL Cells to CD20-Triggered Cell Death by Rituximab and GA101 Via a Different Mechanism. Blood, 2010, 116, 3979-3979.	1.4	0
94	Role for BH3-Only Protein NOXA In Growth-Factor Deprivation and Early Erythropoiesis. Blood, 2010, 116, 4235-4235.	1.4	0
95	Variations of Noxa Levels Caused by p38 MAPK Signaling Result In Heterogeneous Sensitivity to ABT-737 In CD40L-Stimulated CLL Cells. Blood, 2010, 116, 1825-1825.	1.4	1
96	miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood, 2009, 113, 3801-3808.	1.4	258
97	The Presumed Hyporesponsive Behavior of Rheumatoid Arthritis T Lymphocytes Can Be Attributed to Spontaneous Ex Vivo Apoptosis rather than Defects in T Cell Receptor Signaling. Journal of Immunology, 2009, 183, 621-630.	0.8	13
98	A role for HVEM, but not lymphotoxinâ€Î² receptor, in LIGHTâ€induced tumor cell death and chemokine production. European Journal of Immunology, 2009, 39, 2502-2514.	2.9	33
99	Enhanced formation and survival of CD4⁺CD25^{hi}Foxp3⁺T-cells in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2009, 50, 788-801.	1.3	100
100	R-DHAP Is Effective in Fludarabine-Refractory CLL, Possibly Via Upregulation of Pro-Apoptotic P73.. Blood, 2009, 114, 3449-3449.	1.4	0
101	Whole-Genome Scanning by Array Comparative Genomic Hybridization as a Clinical Tool for Risk Assessment in Chronic Lymphocytic Leukemia. Journal of Molecular Diagnostics, 2008, 10, 442-451.	2.8	70
102	In vivo Dynamics of Stable Chronic Lymphocytic Leukemia Inversely Correlate with Somatic Hypermutation Levels and Suggest No Major Leukemic Turnover in Bone Marrow. Cancer Research, 2008, 68, 10137-10144.	0.9	52
103	Adequate synapse formation between leukemic B cells and effector T cells following stimulation with artificial TCR ligands. Leukemia and Lymphoma, 2008, 49, 1592-1602.	1.3	2
104	Enhanced Formation and Survival of Regulatory T Cells in CLL.. Blood, 2008, 112, 1065-1065.	1.4	1
105	Mir-34a as Part of the Chemotherapy Resistance Network in Chronic Lymphocytic Leukemia.. Blood, 2008, 112, 1209-1209.	1.4	1
106	Platinum-Based Compounds Induce Expression of p73 and Restores Drug- Sensitivity in p53 Dysfunctional Chronic Lymphocytic Leukemia (CLL) Cells.. Blood, 2008, 112, 2102-2102.	1.4	0
107	CD27-CD70 interactions sensitise naive CD4+ T cells for IL-12-induced Th1 cell development. International Immunology, 2007, 19, 713-718.	4.0	104
108	Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood, 2007, 109, 1660-1668.	1.4	147

#	Article	IF	Citations
109	Withdrawal symptoms on display: Bcl-2 members under investigation. Trends in Immunology, 2007, 28, 26-32.	6.8	18
110	c-Abl Kinase Inhibitors Overcome CD40-Mediated Drug Resistance in CLL.. Blood, 2007, 110, 3078-3078.	1.4	2
111	In Vivo Tumor Dynamic Studies in Stable CLL Show an Association between CLL Turnover Rates and IgVH Mutational Status and Provide Evidence That the Bone Marrow Is Not a Major Site of Neoplastic Cell Generation.. Blood, 2007, 110, 1128-1128.	1.4	0
112	GSI-1, a Putative Notch Inhibitor, Induces Apoptosis in B-CLL Cells Via Proteasomal Inhibition and Noxa Upregulation.. Blood, 2007, 110, 3113-3113.	1.4	1
113	The Noxa/Mcl-1 Axis Regulates Susceptibility to Apoptosis under Glucose Limitation in Dividing T Cells. Immunity, 2006, 24, 703-716.	14.3	161
114	Attacking Oncogene Addiction in B-CLL: Seliciclib First Engages the Mcl-1/Noxa Axis, after Which Gradual Exhaustion of Bcl-2 Protection Leads to Bax Activation.. Blood, 2006, 108, 2103-2103.	1.4	0
115	B-cell antigen receptor-induced apoptosis: looking for clues. Immunology Letters, 2005, 96, 187-194.	2.5	13
116	Redirection of CMV Specific CTL towards B-CLL Via CD20 Targeted HLA/CMV Complexes.. Blood, 2005, 106, 449-449.	1.4	3
117	The Novel Cancer Drug Seliciclib Engages the Mitochondrial Apoptosis Pathway Via the Mcl-1/Noxa Axis in CLL.. Blood, 2005, 106, 2983-2983.	1.4	0
118	Requirement for Aspartate-cleaved Bid in Apoptosis Signaling by DNA-damaging Anti-cancer Regimens. Journal of Biological Chemistry, 2004, 279, 28771-28780.	3.4	37
119	Autologous cytomegalovirus-specific T cells as effector cells in immunotherapy of B cell chronic lymphocytic leukaemia. British Journal of Haematology, 2004, 126, 512-516.	2.5	12
120	CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack. British Journal of Haematology, 2004, 127, 404-415.	2.5	65
121	APRIL promotes B-1 cell-associated neoplasm. Cancer Cell, 2004, 6, 399-408.	16.8	144
122	Apoptosis via the B cell antigen receptor requires Bax translocation and involves mitochondrial depolarization, cytochrome C release, and caspase-9 activation. European Journal of Immunology, 2004, 34, 1950-1960.	2.9	40
123	Autologous CMV-Specific T Cells as Effector Cells in Immunotherapy of B Cell Chronic Lymphocytic Leukemia.. Blood, 2004, 104, 2512-2512.	1.4	0
124	Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways. Nucleic Acids Research, 2003, 31, 153e-153.	14.5	139
125	The Functional Integrity of the Serpin Domain of C1-inhibitor Depends on the Unique N-terminal Domain, as Revealed by a Pathological Mutant. Journal of Biological Chemistry, 2003, 278, 29463-29470.	3.4	39
126	TR3 Orphan Receptor Is Expressed in Vascular Endothelial Cells and Mediates Cell Cycle Arrest. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 1535-1540.	2.4	61

#	Article	IF	Citations
127	Prevention of B cell antigen receptor-induced apoptosis by ligation of CD40 occurs downstream of cell cycle regulation. International Immunology, 2002, 14, 973-982.	4.0	20
128	Human sprouty 4, a new ras antagonist on 5q31, interacts with the dual specificity kinase TESK1. FEBS Journal, 2002, 269, 2546-2556.	0.2	76
129	Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries. Journal of Molecular Biology, 2001, 305, 773-783.	4.2	41
130	High-density mutagenesis by combined DNA shuffling and phage display to assign essential amino acid residues in protein-protein interactions: application to study structure-function of plasminogen activation inhibitor 1 (PAI-I). Journal of Molecular Biology, 2000, 301, 1135-1147.	4.2	50
131	Selection of peptides that bind to plasminogen activator inhibitor 1 (PAI-1) using random peptide phage-display libraries. FEBS Letters, 1998, 431, 170-174.	2.8	18
132	Modulation of Contact System Proteases by Glycosaminoglycans. Journal of Biological Chemistry, 1996, 271, 12913-12918.	3.4	89
133	Characterization of C1 Inhibitor-Ta. Journal of Biological Chemistry, 1996, 271, 24307-24312.	3.4	27
134	COOH-terminal Substitutions in the Serpin C1 Inhibitor That Cause Loop Overinsertion and Subsequent Multimerization. Journal of Biological Chemistry, 1995, 270, 2579-2587.	3.4	94
135	C1 inhibitor hinge region mutations produce dysfunction by different mechanisms. Nature Genetics, 1992, 1, 354-358.	21.4	68